EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study

Nina U Gelineau iD, Lieke M J van Zogchel iD, Boris De Carolis, Esther M van Wezel, Lily Zappeij-Kannegieter iD, Ahmad Javadi, Roswitha Schumacher-Kuckelkorn, Thorsten Simon iD, Frank Berthold, Max M van Noesel iD, Marta Fiocco iD, Janine Stutterheim iD und 3 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00235 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Nina U Gelineau und 14 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Neuroblastoma, Neoplasm, Residual. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE About 60% of patients with high-risk neuroblastoma relapse. Specific mRNA detection in bone marrow (BM) by reverse transcriptase quantitative PCR (RT-qPCR) is associated with survival outcomes. Peripheral blood (PB) sampling is less invasive. Therefore, we prospectively validated an RT-qPCR panel of neuroblastoma mRNA in PB of patients with high-risk neuroblastoma, treated in NB2004-HR (GPOH) and NBL2009 (DCOG). METHODS From 312 patients, 634 PB samples were prospectively collected (2009-2017) at diagnosis, after two cycles and end-of-induction therapy. RT-qPCR was performed using our panel of neuroblastoma mRNA markers: PHOX2B , TH , DDC , CHRNA3 , and DBH . Results were compared with paired BM samples. The association between neuroblastoma detection and event-free survival (EFS) and overall survival (OS) was estimated using Kaplan-Meier's methodology and multivariable Cox regression model. RESULTS Clear correlation between calculated infiltration by neuroblastoma mRNA expression in PB and BM was seen at diagnosis ( r s 0.70 [95% CI, 0.62 to 0.76]), and heterogeneity was seen after two cycles (0.37 [95% CI, 0.12 to 0.58]) and end of induction (0.61 [95% CI, 0.10 to 0.87]). mRNA expression was significantly lower in PB compared with BM. At diagnosis, PB infiltration ≥1% was a prognostic factor for survival: adjusted hazard ratio (HR) was 2.37 [95% CI, 1.56 to 3.60] for EFS and 2.60 [1.65-4.08] for OS. At the end of induction, PHOX2B positivity in PB samples (n = 11) was associated with poor outcomes: HR 3.06 [1.51-6.20] for EFS and 2.88 [1.36-6.11] for OS. In patients with ≥10% BM infiltration at diagnosis, detection of the mRNA panel in PB samples could significantly distinguish between survival groups; the adjusted HR of PB infiltration ≥1% was 2.09 [1.01-4.30] for OS. CONCLUSION PB infiltration is associated with EFS and OS at diagnosis; it is also significantly associated with survival outcomes of patients with ≥10% BM infiltration at diagnosis. During follow-up, neuroblastoma mRNA detection in PB can be of added value, when BM analysis is not possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaNeoplasm, ResidualHumansProspective StudiesFemaleMaleChild, PreschoolInfantChildRNA, MessengerBiomarkers, Tumor

Substanzen

RNA, MessengerBiomarkers, Tumor

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.
  • Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory of the AMC-University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Pediatric Hematology and Oncology, Children's Hospital-University of Cologne, Cologne, Germany.
  • Division Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Mathematical Institute, Leiden University, Leiden, the Netherlands.
  • Medical Statistics Section, Department of Biomedical Data Science, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Nina U Gelineau, Lieke M J van Zogchel, Lily Zappeij-Kannegieter, Thorsten Simon, Max M van Noesel, Marta Fiocco, Janine Stutterheim, C Ellen van der Schoot, Barbara Hero, Godelieve A M Tytgat

Zitieren

APA

Gelineau, N. U., van Zogchel, L. M. J., De Carolis, B., van Wezel, E. M., Zappeij-Kannegieter, L., Javadi, A., Schumacher-Kuckelkorn, R., Simon, T., Berthold, F., van Noesel, M. M., Fiocco, M., Stutterheim, J., Ellen van der Schoot, C., Hero, B., & Tytgat, G. A. M. (2025). Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study. JCO Precision Oncology. https://doi.org/10.1200/po-25-00235

Vancouver

Gelineau NU, van Zogchel LMJ, De Carolis B, van Wezel EM, Zappeij-Kannegieter L, Javadi A, et al. Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study. JCO Precision Oncology. 2025. doi:10.1200/po-25-00235

BibTeX
@article{Gelineau2025,
  author = {Gelineau, Nina U and van Zogchel, Lieke M J and De Carolis, Boris and van Wezel, Esther M and Zappeij-Kannegieter, Lily and Javadi, Ahmad and Schumacher-Kuckelkorn, Roswitha and Simon, Thorsten and Berthold, Frank and van Noesel, Max M and Fiocco, Marta and Stutterheim, Janine and Ellen van der Schoot, C and Hero, Barbara and Tytgat, Godelieve A M},
  title = {Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00235}
}
Kostenlos starten →